Investment analysts at Zacks Research assumed coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN – Get Free Report) in a note issued to investors on Wednesday, Zacks reports. The firm set a “hold” rating on the stock.
RTSN has been the subject of a number of other research reports. Guggenheim assumed coverage on shares of Retension Pharmaceuticals in a report on Monday. They issued a “buy” rating and a $55.00 price target for the company. Leerink Partners assumed coverage on shares of Retension Pharmaceuticals in a report on Tuesday. They set a “strong-buy” rating on the stock. Finally, Oppenheimer initiated coverage on shares of Retension Pharmaceuticals in a report on Tuesday. They set an “outperform” rating and a $50.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $52.50.
Read Our Latest Analysis on RTSN
Retension Pharmaceuticals Trading Down 7.6%
NASDAQ:RTSN opened at $10.72 on Wednesday. Retension Pharmaceuticals has a 1 year low of $9.66 and a 1 year high of $18.64.
Insider Buying and Selling
In related news, Director Franklin Berger acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average cost of $12.00 per share, for a total transaction of $120,000.00. Following the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $120,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Eric Keller bought 20,800 shares of Retension Pharmaceuticals stock in a transaction that occurred on Tuesday, October 13th. The stock was bought at an average cost of $12.00 per share, for a total transaction of $249,600.00. Following the purchase, the chief executive officer owned 423,377 shares in the company, valued at $5,080,524. This represents a 5.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.
Retension Pharmaceuticals Company Profile
We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.
Featured Articles
- Five stocks we like better than Retension Pharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Retension Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
